Eloxx Pharmaceuticals appoints Daniel Geffken as Principal Accounting Officer

Eloxx Pharmaceuticals, Inc.

Daniel Geffken, Interim CFO since April 1, 2021, added role of Principal Accounting Officer on August 17, 2021.
Geffken provides services through Danforth Advisors, LLC.
No departure or change in CFO role; Geffken remains Principal Financial Officer.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel Geffken

Principal Accounting Officer

ELOX · Eloxx Pharmaceuticals, Inc.

Effective: 2021-08-17
Filed: August 20, 2021, 7:59 PM ET

On August 17, 2021, the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed the Company’s Interim Chief Financial Officer, Daniel Geffken, to serve as the Company’s Principal Accounting Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Geffken was appointed as Principal Accounting Officer at Eloxx Pharmaceuticals, Inc..

Action: appointed
Role: Principal Accounting Officer

Exact text from the filing

On August 17, 2021, the Board of Directors (the “Board”) of Eloxx Pharmaceuticals, Inc. (the “Company”) appointed the Company’s Interim Chief Financial Officer, Daniel Geffken, to serve as the Company’s Principal Accounting Officer.

View on SEC.gov

Eloxx Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-21-108145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.